Updated:
Precision Medicine Group
Precision Medicine Group is Hunan province's state-owned commercializer of genomic diagnostics and oncology infrastructure, backed by a 3.5B yuan parent.
Precision Medicine Group
Precision Medicine Group was established as a state-owned operating company under the Hunan Provincial State-owned Assets Supervision and Administration Commission. The parent, Hunan Pharmaceutical Development Investment Group, was capitalized at 3.5 billion yuan and charged with consolidating the province's pharmaceutical supply chain, medical devices, testing, and health investment assets. Precision Medicine Group was set up as the cell and molecular technology arm, focusing on commercializing advanced diagnostics within Hunan's public health system. It pursues three integrated service lines: regional medical testing center networks, precision oncology ward solutions, and a women's health protocol spanning genetic screening to nutrition. Its oncology platform uses humanized mouse models (Hu-HSC-3D-PDX), immune organoids, and bispecific nanobody discovery to support treatment response monitoring tool called cfDNA tumor assessment. The women's health line is anchored by Jinrong Granules, a Category 1.1 innovative drug approved for breast nodule management. Consumer-facing brands include Chongren Era for women's health, Douluoshi for tumor wards, and TanYin for at-home genomic testing kits covering HPV genotyping, tumor early screening, and nutritional genomics. Shareholders include a provincial guidance fund (Hunan Emerging Industry Guidance Investment Partnership), a pharmaceutical industry fund, an investment vehicle linked to Laobaixing Pharmacy Chain, and several employee and strategic investor partnerships. The firm lists academic collaborators at the National University of Singapore, Rutgers, Central South University, and Hunan University of Chinese Medicine. No deployment total or headcount has been disclosed. Its structural distinction is operating as a government-mandated channel for laboratory-developed tests — a nationally regulated gray zone since 2015 — giving it a first-mover advantage as the province's designated LDT commercialization platform. Unlike a typical venture-backed diagnostics startup, Precision Medicine Group absorbs regulatory and reimbursement risk by embedding its services directly into public hospital procurement and provincial health bureau initiatives.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Changsha
Corporate office
长沙市芙蓉区通程国际大酒店内写字楼第20层, Changsha, Hunan, China
Sector focus
Frequently asked questions
Is Precision Medicine Group a family office or an operating company?
It is a state-owned operating company, not a family office. The firm sits under Hunan Pharmaceutical Development Investment Group, which was capitalized by the Hunan provincial government and consolidated multiple state pharmaceutical assets. Precision Medicine Group is the precision medicine and genomics commercialization subsidiary within that structure.
What is the firm's relationship with Hunan Pharmaceutical Group?
Precision Medicine Group is a subsidiary of Hunan Pharmaceutical Group, which itself is a holding under Hunan Pharmaceutical Development Investment Group. The parent was formed to be the provincial 'chain leader' enterprise across the pharmaceutical, medical device, testing, and health investment sectors. Precision Medicine Group serves as the molecular diagnostics and precision oncology business unit.
How does the firm commercialize its diagnostics?
It builds and operates three channel types: regional medical testing centers that consolidate lab services across hospital networks, precision oncology wards within hospitals using its own organoid and mouse model platforms, and direct-to-consumer genomic testing kits under the TanYin brand covering HPV, tumor screening, and nutrition. Reimbursement flows through public hospital procurement and provincial health bureau programs.
What is the cfDNA tumor assessment product?
The cfDNA assay measures total concentration and integrity of circulating cell-free DNA in peripheral blood. After bioinformatics calibration it generates a CTE index that the firm markets for real-time treatment response evaluation and recurrence monitoring across breast, liver, lung, gastric, and pediatric solid tumors. The platform is positioned as a lower-cost alternative to frequent imaging.
Who are the firm's research collaborators?
Listed academic collaborators include the National University of Singapore, Rutgers University, Central South University, Hunan University, and Hunan University of Chinese Medicine. These collaborations support the firm's organoid models, bispecific nanobody discovery, and companion diagnostics pipeline, though specific joint research programs have not been disclosed.
Does the firm raise outside capital or invest in external companies?
Precision Medicine Group does not disclose any venture investment activity. Its shareholder roster includes provincial-level guidance funds and a pharma-sector investment partnership — these provided the initial registered capital — but the firm operates as a service and commercialization vehicle rather than an external fund manager or GP.
What is Jinrong Granules and why is it notable?
Jinrong Granules is a traditional Chinese medicine product categorized as a national Category 1.1 innovative drug and the only one approved by the NMPA for breast nodule management. Precision Medicine Group uses it as the anchor therapy in its women's health protocol, combining it with HPV genotyping and nutritional supplementation into a bundled 'full lifecycle' offering.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: